Biobanking Market Size, Share and Industry Analysis, Report 2025-2033

Biobanking Industry

Summary:

● The global biobanking market size reached USD 64.3 Billion in 2024.
● The market is expected to reach USD 101.1 Billion by 2033, exhibiting a growth rate (CAGR) of 5.2% from 2025-2033.
● North America leads the market, accounting for the largest biobanking market share.
● Blood products account for the majority of the market share in the specimen type segment as they are relatively easy to collect and store, ensuring consistent supply.
● Disease-oriented biobanks hold the largest share in the biobanking industry.
● Research represents the leading application segment.
● Pharma and biotech companies remain a dominant segment in the market as they rely on biobanks to access diverse genetic data, biomarkers, and disease samples, propelling research and innovation.
● The rising consumer preference for personalized treatment is a primary driver of the biobanking market.
● The biobanking market growth and forecast highlight a significant rise due to technological advancements and supportive government programs.

Industry Trends and Drivers:

● Growing demand for personalized medicine:

The increasing demand for personalized medicine across the globe is one of the major factors boosting the biobanking market share. Personalized or precision medicine tailors medical treatments to individual genetic profiles, allowing for more effective treatments with fewer side effects. Biobanks play a vital role by providing access to diverse biological samples, including blood, tissue, and DNA, which are essential for research on genetic variations and disease susceptibility. These samples help researchers identify biomarkers, enabling the development of targeted therapies and the creation of personalized treatment plans. As the healthcare industry continues to shift toward personalized approaches, biobanks are in high demand, contributing to market growth.

● Advancements in genomics and biotechnology:

The biobanking market trends indicate that advancements in genomics and biotechnology have significantly expanded the applications of biobanks in medical research. Technologies such as next-generation sequencing (NGS) and gene editing have expedited the discovery of disease mechanisms and therapeutic targets, increasing the need for biological samples from biobanks. Biobanks store a vast array of samples, including genomic data, which are vital for understanding complex diseases such as cancer, neurological disorders, and genetic diseases. As scientific research advances, the need for well-maintained and diverse biobanks is growing as they provide the raw materials required for new breakthroughs in diagnostics, drug discovery, and disease prevention. These technological advancements are significantly boosting the biobanking demand.

● Support from government and private sectors:

Government and private sector investments in medical research are driving the biobanking market size. Public funding, alongside collaborations between government institutions and research organizations, has helped establish large-scale biobanks that support diverse research initiatives. In addition to this, pharmaceutical and biotechnology companies are investing in biobanks to expedite drug development and clinical trials. This financial support is fostering innovation and growth in the biobanking sector, enabling the creation of more specialized biobanks, such as disease-specific or population-based collections. As governments and private companies continue to recognize the value of biobanks in advancing healthcare, their involvement will ensure the continued expansion of the industry.

For an in-depth analysis, you can request a sample copy of the report: https://www.imarcgroup.com/biobanking-market/requestsample

Biobanking Market Report Segmentation:

Breakup By Specimen Type:

● Blood Products
● Solid Tissue
● Cell Lines
● Nucleic Acid
● Others

Blood products account for the majority of shares due to their high demand for medical research and diagnostics.

Breakup By Biobank Type:

● Population-based Biobanks
● Disease-oriented Biobanks

Disease-oriented biobanks dominate the market due to their focus on specific conditions, enabling targeted research and precision medicine.

Breakup By Application:

● Therapeutics
● Research

Research exhibits a clear dominance as biobanks provide essential biological samples for scientific studies, driving innovations in medicine and health.

Breakup By End User:

● Academic Institutions
● Pharma and Biotech Companies

Pharma and biotech companies represent the majority of shares due to their need for high-quality biological samples in drug development and clinical trials.

Breakup By Region:

● North America (United States, Canada)
● Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
● Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
● Latin America (Brazil, Mexico, Others)
● Middle East and Africa

North America holds the leading position owing to a large market for biobanking driven by its advanced healthcare infrastructure and significant investments in medical research.

Top Biobanking Market Leaders:

● Brooks Automation Inc.
● Bay Biosciences LLC
● Boca Biolistics
● Ctibiotech
● Cureline Inc.
● Firalis
● Greiner Bio-One International GmbH
● Hamilton Company
● Merck KGaA
● ProteoGenex Inc.
● Thermo Fisher Scientific Inc.
● VWR Corporation (Avantor Inc.)

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Contact Us:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

This release was published on openPR.